GRAND RAPIDS, Mich., Dec. 5, 2016 /PRNewswire/ -- NxGen MDx announced today that it brought its NxGen Informed Prenatal Test in-house.
“By bringing the test in house, we’ve been able to improve customer service through shortened turnaround times and at the same time keep costs down for patients,” says Alan Mack, CEO of NxGen MDx.
A decrease in turnaround times by 25% combined with an increase in test volume has led to more job opportunities at the Grand Rapid headquarters.
The NxGen Informed Prenatal Test uses the illumina NGS platform and can, with the highest degree of accuracy, determine the presence of chromosomal aneuploidies in a developing fetus. The test can be done as early as 10 weeks into the pregnancy and has no limitations in terms of ethnicity, body mass index, assisted reproductive technology, or egg donor cases.
Patients can use the information this test provides to learn more about the risk of non-inherited chromosomal conditions and weigh the benefits and risks of further invasive diagnostic procedures.
About NxGen MDx
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGEN MDx’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGEN MDx is located in Grand Rapids, Michigan. To learn more, visit the company’s website at www.nxgenmdx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxgen-mdx-announces-the-move-of-their-non-invasive-prenatal-test-in-house-300372896.html
SOURCE NxGEN MDx
